REQUEST PER YOUR SOME ABAN	NDONED APPLICA	TION UNDER 37 CFR 1.14(a
	In re Application of	
	Lobb	et al.
	- Alimana	Fied
	08 373,	82,1 1,11,1,2
2.	Group Art Unit E	Zautnet
		TECN 99
		Paper No.
Assistant Commissioner for Patents		TER 1
Washington, DC 20231		VED 1600/ AM 9:
	_	2 2
I hereby request access under 37 CFR 1. Identified ABANDONED application, which	,14(a)(3)(iv) to the appu tris: (CHECK ONE;	cation the receits of the species
identified ABANDONED application, which (A) referred to in United States Pater	11 Number 5932	2214 column
	VII = 1	Jian as set forth in 37 CFR 1.11. No.
Application No	filed	on page of
paper number		f an application that is open to publi
inspector, i.e., Application into.		-
(0) an application in which the application to the public.	icant has filed an autho	rization to lay open the complete
Please direct any correspondence cond	cerning this request to t	he following address:
Please direct any Concepting the	,	₹
-0	·	
In chay Cheey ai	Dane.	8/11/99
Sie		Date
SOMCHAY CHIM	JYAVONG	FOR PTO USE ONLY
Typed or printed name		Annoyed by:
•		(IIIISSE)
		Unit:



United States Patent [19]

Lobb et al.

[11] Patent Number:

and the state of t

5,932,214

[45] Date of Patent:

Aug. 3, 1999

[54] TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH VLA-4 BLOCKERS

[75] Inventors: Roy R. Lobb, Westwood; Linda C. Burkly, West Newton, both of Mass.

[73] Assignee: Biogen, Inc., Cambridge, Mass.

[21] Appl. No.: 08/950,660

[22] Filed: Oct. 15, 1997

Related U.S. Application Data

[62ntinuation of application No. 08/456,124, May 31, 1995., abandoned, which is a continuation-in-part of application No. 08/373,857, Jan. 18, 1995., abandoned, which is a continuation-in-part of application No. 08/284,603, Aug. 11, 1994., abandoned, which is a continuation-in-part of application No. 07/835,139, filed as application No. PCT/US93/00924, Feb. 2, 1993., abandoned

[51]	Int. Cl. 6
[52]	U.S. Cl
	424/133.1; 424/134.1; 424/136.1; 424/141.1
	424/143.4; 424/153.1; 424/154.1; 514/2
	514/8; 514/885; 530/350; 530/387.1; 530/387.3
	530/388.1; 530/388.2; 530/388.22; 530/388.7
	530/388.73; 530/388.75

[56] References Cited

U.S. PATENT DOCUMENTS

		Boss et al 435/68
4,833,092	5/1989	Geysen 436/501
		Capon et al
5,272,263	12/1993	Hession et al
5,730,978	3/1998	Wayner .

FOREIGN PATENT DOCUMENTS

0 314 863	5/1989	European Pat. Off
0 330 506	9/1989	European Pat. Off
0 333 517	9/1989	European Pat. Off
0 346 078	12/1989	European Pat. Off
WO 90/03400	4/1990	WIPÒ.
WO 90/13300	11/1990	WIPO .
9103252	3/1991	WIPO .
WO 92/00751	1/1992	WIPO .
WO 93/13798	1/1992	WIPO .
WO 95/19790	7/1995	WIPO .

OTHER PUBLICATIONS

Jakubowski, et al. "Vascular Cell Adhesion Molecule (VCAM)-Ig Fusion Protein Defines Distinct Affinity States of the Very Late Antigen-4 (VLA-4) Receptor" Cell Adhesion and Communication 3:131-142 (1995).

Brown, Jr., P. et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival" *Proc. Natl. Acad. Sci. USA* 88:2663-2667 (1990).

Burkly, L. et al., "Signaling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA-4 Promotes CD3-dependent T Cell Proliferation" Eur. J. Immunol. 21:2871-2875 (1991).

Clackson, T. et al., "Making Antibody Fragments Using Phage Display Libraries" *Nature* 352:624-628 (1991).

Co, M.S. et al., "Humanized Antibodies for Antiviral Therapy" Proc. Natl. Acad. Sci. USA 88:2869-2873 (1990).

Damle, N. et al., "Vascular Cell Adhesion Molecule 1 Induces T-cell Antigen Receptor-dependent Activation of CD4+ T Lymphocytes" *Proc. Natl. Acad. Sci. USA* 88:6403-6407 (1991).

Devlin, J. et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules" *Science* 249:400–406 (1990).

Dobrina, A. et al., "Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells" *J. Clin. Invest.* 88:20–26 (1991).

Elices, M.J. et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site" *Cell* 60:577-584 (1990).

Freedman, A. et al., "Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110" Science 249:1030-1033 (1990).

Harris, W.J. and S. Emery, "Therapeutic antibodies—the coming of age" TIBTECH 11: 42-44 (1993).

Hemler, M. E. et al., "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides" J. Biol. Chem. 262(24):11478-11485 (1987).

Holzmann, B. and I.L. Weissman, "Integrin Molecules Involved in Lymphocyte Homing to Peyer's Patches" *Immunolical Reviews* 0(108):45-61 (1989).

Podolsky, D.K. et al., "Colonic Mucin Composition in Primates Selective Alterations Associated with Spontaneous Colitis in the Cotton-top Tamarin" *Gastroent.* 88:20–25 (1985).

Podolsky, D.K. et al., "Spontaneous Colitis In Cotton-Top Tamarins: Histologic, Clinical and Biochemical Features of an Animal Model of Chromic Colitis" *Digestive Diseases and Sciences* 30(4):396 (A-32) (1985).

Pulido, R. et al., "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4" J. Biol. Chem. 266(16):10241-10245 (1991).

Rice, G.E. et al., "Vascular and Nonvascular Expression of INCAM-110", Am. J. Pathology 138(2):385-393 (1991).

Riechmann, L. et al., "Reshaping Human Antibodies for Therapy" *Nature* 332:323–327 (1988).

(List continued on next page.)

Primary Examiner—Christina Y. Chan Assistant Examiner—Phillip Gambel Attorney, Agent, or Firm—Fish & Richardson P.C.

[57] ABSTRACT

A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.

15 Claims, 8 Drawing Sheets